Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

被引：50
作者：
Silverdale, MA
Nicholson, SL
Crossman, AR
Brotchie, JM
机构：
[1] Hope Hosp, Dept Neurol, Salford M6 8HD, Lancs, England
[2] Univ Manchester, Sch Biol Sci, Manchester Movement Disorder Lab, Manchester, Lancs, England
[3] Motac Neurosci Ltd, Manchester, Lancs, England
[4] Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada
来源：
MOVEMENT DISORDERS | 2005年 / 20卷 / 04期
基金：
中国国家自然科学基金;
关键词：
topiramate; dyskinesia; MPTP; Parkinson's disease;
D O I：
10.1002/mds.20345
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, Without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levoclopa-induced dyskinesia in patients with Parkinson's disease. (c) 2004 Movement Disorder Society.
引用
收藏
页码：403 / 409
页数：7
相关论文
共 38 条
  • [1] Abou-Khalil B, 2000, EPILEPSIA, V41, pS72
  • [2] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    Ahlskog, JE
    Muenter, MD
    [J]. MOVEMENT DISORDERS, 2001, 16 (03) : 448 - 458
  • [3] A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures
    Aldenkamp, AP
    Baker, G
    Mulder, OG
    Chadwick, D
    Cooper, P
    Doelman, J
    Duncan, R
    Gassmann-Mayer, C
    de Haan, GJ
    Hughson, C
    Hulsman, J
    Overweg, J
    Pledger, G
    Rentmeester, TW
    Riaz, H
    Wroe, S
    [J]. EPILEPSIA, 2000, 41 (09) : 1167 - 1178
  • [4] LESION OF THE SUBTHALAMIC NUCLEUS FOR THE ALLEVIATION OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)-INDUCED PARKINSONISM IN THE PRIMATE
    AZIZ, TZ
    PEGGS, D
    SAMBROOK, MA
    CROSSMAN, AR
    [J]. MOVEMENT DISORDERS, 1991, 6 (04) : 288 - 292
  • [5] Adenosine A2A receptor antagonist treatment of Parkinson's disease
    Bara-Jimenez, W
    Sherzai, A
    Dimitrova, T
    Favit, A
    Bibbiani, F
    Gillespie, M
    Morris, MJ
    Mouradian, MM
    Chase, TN
    [J]. NEUROLOGY, 2003, 61 (03) : 293 - 296
  • [6] REVERSAL OF EXPERIMENTAL PARKINSONISM BY LESIONS OF THE SUBTHALAMIC NUCLEUS
    BERGMAN, H
    WICHMANN, T
    DELONG, MR
    [J]. SCIENCE, 1990, 249 (4975) : 1436 - 1438
  • [7] Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
    Chase, TN
    Oh, JD
    [J]. TRENDS IN NEUROSCIENCES, 2000, 23 (10) : S86 - S91
  • [8] AROMATIC AMINO ACIDS AND MODIFICATION OF PARKINSONISM
    COTZIAS, GC
    VANWOERT, MH
    SCHIFFER, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) : 374 - &
  • [9] Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons
    DeLorenzo, RJ
    Sombati, S
    Coulter, DA
    [J]. EPILEPSIA, 2000, 41 : S40 - S44
  • [10] Topiramate as an inhibitor of carbonic anhydrase isoenzymes
    Dodgson, SJ
    Shank, RP
    Maryanoff, BE
    [J]. EPILEPSIA, 2000, 41 : S35 - S39
1234